NHS Surgeon First in Europe to Implant TELA Bio's OviTex® LPR Reinforced Tissue Matrix
July 21 2021 - 8:28AM
TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical
technology company focused on designing, developing, and marketing
innovative tissue reinforcement materials to address unmet needs in
soft tissue reconstruction, announced today the first use of its
OviTex LPR Reinforced Tissue Matrix in Europe.
Mr. Paul Wilson, Consultant General Surgeon at University
Hospitals of Morecambe Bay NHS Foundation Trust, successfully
performed Europe's first minimally invasive hernia repair with
OviTex LPR. This critical milestone marks the first phase of a
comprehensive commercial launch of OviTex LPR across Europe, which
is expected to commence in Q4 of 2021.
"For years, I've had to adapt my surgical approach to compensate
for the intraoperative limitations of first-gen biologic implants,"
said Mr. Wilson. "OviTex LPR provides superior handling with little
memory, making it very easy to place in the peritoneal cavity,
allowing me to offer the benefits of a minimally invasive hernia
repair to more patients."
Purposefully designed to help facilitate the transition of
complex open hernia procedures to laparoscopic or robotic
approaches, OviTex LPR provides surgeons with a trocar-compatible
reinforced biologic available in a variety of sizes.
"With the addition of LPR to the OviTex portfolio, we believe we
are well positioned to address the increasing demand across the EU
for both minimally invasive surgeries and more natural hernia
repair solutions," said Anne-Marie Burrell, Director Clinical and
Market Development at TELA Bio. "I would like to personally thank
Mr. Paul Wilson for trusting TELA Bio's OviTex Reinforced Tissue
Matrix to care for your patients."
To request more information on the availability of OviTex LPR
contact Anne-Marie Burrell via email at aburrell@telabio.com. Visit
v.telabio.com/gonatural to learn about the clinical advantages of a
More Natural Hernia Repair™ with OviTex Reinforced Tissue
Matrix..
About TELA Bio, Inc.
TELA Bio Inc. (NASDAQ: TELA) is a commercial-stage medical
technology company focused on designing, developing, and marketing
innovative tissue reinforcement materials to address unmet needs in
soft tissue reconstruction. The Company is committed to providing
patients with advanced, economically effective biologic material
repair solutions to minimize long-term exposure to permanent
synthetic materials and improve clinical outcomes. TELA Bio's
OviTex® and OviTex PRS Reinforced Tissue Matrix products are
purposefully designed to address the shortcomings of existing
reinforcement materials in hernia repair, abdominal wall
reconstruction, and plastic and reconstructive surgery. For more
information, visit www.telabio.com.
About OviTexOviTex Reinforced Tissue Matrix is
intended for use as a surgical mesh to reinforce and/or repair soft
tissue where weakness exists. Indications for use include the
repair of hernias and/or abdominal wall defects that require the
use of reinforcing or bridging material to obtain the desired
surgical outcome. Do not use OviTex in patients known to be
sensitive to materials of ovine (sheep) origin. For prescription
use only. For additional important safety information, please see
the OviTex Reinforced BioScaffold Instructions for Use.The
statements made or results achieved by TELA Bio customers described
herein were achieved in their specific setting. Due to variations
in clinical experience and technique, there is no guarantee that
these results are typical. A surgeon must use his or her own
clinical judgment when deciding which products are appropriate for
treatment of a particular patient. Always refer to the package
insert, product label, and/or instructions for use before using any
TELA Bio product. Products may not be available in all markets
because product availability is subject to the regulatory and/or
medical practices in individual markets.
Caution Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations are forward-looking statements and reflect the current
beliefs of TELA's management. These statements are not guarantees
of future performance and are subject to certain risks,
uncertainties and other factors that could cause actual results and
events to differ materially and adversely from those indicated by
such forward-looking statements including, among others, the impact
to our business of the ongoing COVID-19 pandemic, including any
impact on our ability to market our products, demand for our
products due to deferral of procedures using our products or
disruption in our supply chain, our ability to achieve or sustain
profitability, our ability to gain market acceptance for our
products and to accurately forecast and meet customer demand, our
ability to compete successfully, that data from earlier studies
related to our products and interim data from ongoing studies may
not be replicated in later studies or indicative of future data,
our ability to enhance our product offerings, development and
manufacturing problems, capacity constraints or delays in
production of our products, maintenance of coverage and adequate
reimbursement for procedures using our products, product defects or
failures. These and other risks and uncertainties are described
more fully in the "Risk Factors" section and elsewhere in our
filings with the Securities and Exchange Commission and available
at www.sec.gov, including in our Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q. Any forward-looking statements that
we make in this announcement speak only as of the date of this
press release, and TELA assumes no obligation to update
forward-looking statements whether as a result of new information,
future events or otherwise after the date of this press release,
except as required under applicable law.
Investor ContactGreg
Chodaczek347-620-7010 ir@telabio.com
TELA Bio (NASDAQ:TELA)
Historical Stock Chart
From Aug 2024 to Sep 2024
TELA Bio (NASDAQ:TELA)
Historical Stock Chart
From Sep 2023 to Sep 2024